Saturday, October 31, 2026

MicroVision Stock Soars 29% In 10 Sessions: Is It Time To Invest?

ViaNews Editorial Team

November 28, 2023

MicroVision Stock Soars 29% In 10 Sessions: Is It Time To Invest?

(VIANEWS) - MicroVision (NASDAQ: MVIS) shares experienced an astounding 29.15% gain over 10 sessions, rising from EUR1.99 at 2023-11-10 to EUR2.57 by 02:35 EST Tuesday after two consecutive gains. While overall NASDAQ lost ground after its previous downward trend and closed at EUR14,241.02, MicroVision closed with 69.51% below its 52-week high of EUR8.20 at just EUR2.50 as per Tuesday closing prices.

About MicroVision

MicroVision, Inc. is a technology company specializing in developing and selling lidar sensors for automotive safety and autonomous driving applications. Their innovative laser beam scanning technology utilizes MEMS, laser diodes, opto-mechanics, electronics, algorithms, and software - their core business. In addition to that core business, they also create micro display concepts, 1440i MEMS modules, interactive display solutions for smart speakers and home systems as well as first Generation LRL modules; selling these primarily to original equipment Manufacturers/original Design Manufacturers since 1993! Founded by Michael in Redmond Washington

Yearly Analysis

Based on the available data, MicroVision's stock is currently trading below its 52-week high but significantly above its 52-week low - this indicates a sharp decline over the past year while currently showing signs of strength. At 988.9% and 937.3% respectively, investors seem optimistic about the company's sales growth this year and next. This indicates they see potential for greater expansion that could drive the stock price higher. MicroVision currently boasts an EBITDA figure of 191.09, indicating it is producing positive cash flow and that investors should feel secure that MicroVision remains profitable and financially sound. MicroVision stock appears to have a promising outlook, with strong upward trends and significant potential growth potential. To make an informed decision about any investment decision, however, further research and analysis should be performed prior to making a final decision.

Technical Analysis

MicroVision stock has recently experienced an unpredictable ride, fluctuating significantly above and below its moving averages. MicroVision's 50-day moving average stands at EUR2.12, while its 200-day average sits at EUR2.90; these numbers demonstrate just how unpredictable its price has been recently. MicroVision's last reported volume of 2366037 was 51.97% lower than its average volume of 1807130; this indicates an apparent lack of interest for its stocks which may explain their fluctuating prices. At first glance, it appears that volatility of this stock has been quite high over the past week, month, and quarter. Intraday variation averages were 1.55%, 1.53% and 3.53% in each case respectively - its highest amplitude being 5.07% in one week, 4.96% in another, and 3.53% over four quarters. According to the stochastic oscillator, which provides an indicator of overbought and oversold conditions, MicroVision stock appears to be oversold (=20). This suggests that MicroVision stock could currently be undervalued but may show signs of rebound within months. Overall, MicroVision stock is currently in a state of flux due to various influences affecting its price. Investors should exercise extreme caution in monitoring MicroVision's movements over the next weeks in order to make informed decisions on whether or not to buy, hold, or sell.

Quarter Analysis

It seems highly unlikely for a company's sales growth to surge by 480% within one quarter, as stated. This information appears to be either inaccurate or misrepresented. Regarding growth estimates for both quarters, negative growth estimates of 12.5% indicate sales decline from the prior quarter while positive growth estimates of 18.2% suggest sales increases relative to current quarter. Note that these growth rates are only estimates, as actual results may differ significantly. It's essential to also take into account other factors like company financial health, industry trends and competition before making investment decisions.

Equity Analysis

MicroVision currently generates an EPS of EUR-0.43, meaning they are not making profits for shareholders at present. Additionally, the company's return on equity (ROE) for the last twelve months stands at negative -83.29% indicating that it is failing to utilize shareholder's equity effectively to generate profits and drive shareholder value creation. MicroVision investors should exercise caution before considering investing in it, as its current financial performance does not indicate an established and profitable company. Therefore, investors must closely follow and analyse MicroVision before making informed investment decisions based on fundamental analysis of its business.

More news about MicroVision (MVIS).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com